Other compounds showed a good inhibitory ability against Spike-ACE2 complex both for Delta and Omicron variants: repaglinide, a hypoglycemic drug, approved for the treatment (in combination with rosiglitazone or pioglitazone) of type 2 diabetes54; RPR121056-d3, a metabolite of Irinotecan (CPT-11), already approved as antineoplastic agent55; itraconazole, already approved for the treatment of certain fungal infections (candidiasis and histoplasmosis)56. The gene discussed is ACE2; the disease is histoplasmosis.